Research programme: glycogen synthase kinase 3 inhibitors - NosciraAlternative Names: GSK-3 inhibitors - Noscira; NP-103; NP01139; NP060103; Palinurin; Tricantin
Latest Information Update: 07 Mar 2013
At a glance
- Originator Neuropharma
- Developer Noscira
- Class Small molecules; Thiadiazoles
- Mechanism of Action Glycogen synthase kinase 3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Alzheimer's disease